Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer - Concepedia

Concepedia

Publication | Open Access

Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer

DOI Full Paper Access

56

Citations

38

References

2012

Year

Amanda Kirane, Jason E. Toombs, Katherine T. Ostapoff, Juliet G. Carbon, Sara Zaknoen, Jordan Braunfeld, Roderich E. Schwarz, Francis Burrows, Rolf A. Brekken

Clinical Cancer Research

Abstract

Apricoxib robustly reverses EMT and augments standard therapy without reducing microvessel density and warrants further clinical evaluation in patients with pancreatic cancer.

References

	Year	Citations

Page 1